Nitish K Dhingra

Jan 10, 2024 | inria.hal.science | Nitish K Dhingra |Subodh Verma |Javed Butler |Baylor Scott

Article Dans Une Revue JACC: Heart Failure Année : 2024 Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF Fichier principal 1-s2.0-S2213177923004535-main.pdf (959.7 Ko) Télécharger le fichier 1-s2.0-S2213177923004535-mmc1.pdf (583.92 Ko) Télécharger le fichier Origine : Fichiers éditeurs autorisés sur une archive ouverte hal-04384319 , version 1 (10-01-2024) Nitish K Dhingra, Subodh Verma, Javed Butler, Stefan D Anker, Joao Pedro Ferreira, et al.. Efficacy and...

Jan 1, 2024 | jacc.org | Nitish K Dhingra |Subodh Verma |Javed Butler |Stefan Anker

IntroductionIn patients with heart failure with reduced ejection fraction (HFrEF), the sodium glucose co-transporter 2 (SGLT2) inhibitors empagliflozin and dapagliflozin reduce the rates of cardiovascular (CV) death or heart failure (HF) hospitalization by about 25%.1-4 These benefits are observed independently of glycemic status5,6 and down to an eGFR of 20 mL/min/1.73 m2.